Novonesis Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Novonesis heeft een totaal eigen vermogen van €11.0B en een totale schuld van €2.0B, wat de schuld-eigenvermogensverhouding op 18.1% brengt. De totale activa en totale passiva bedragen respectievelijk €15.3B en €4.2B. De EBIT Novonesis is €525.0M waardoor de rentedekking 15.7 is. Het heeft contanten en kortetermijnbeleggingen van €260.8M.
Belangrijke informatie
18.1%
Verhouding schuld/eigen vermogen
€1.99b
Schuld
Rente dekkingsratio | 15.7x |
Contant | €260.80m |
Aandelen | €11.01b |
Totaal verplichtingen | €4.25b |
Totaal activa | €15.25b |
Recente financiële gezondheidsupdates
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 27Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Jun 24Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Mar 26Is Novozymes (CPH:NZYM B) Using Too Much Debt?
Dec 23These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 13Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly
Jun 13Recent updates
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 27An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued
Sep 05Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively
Jul 09Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Jun 24Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)
May 02Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively
Apr 07Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Mar 26Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?
Mar 12Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues
Feb 04Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)
Jan 29Is Novozymes (CPH:NZYM B) Using Too Much Debt?
Dec 23Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture
Dec 05A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)
Oct 14These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 13The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence
Aug 29Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)
Jul 13Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly
Jun 13Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital
May 29Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( €1.8B ) NSIS B } overtreffen de korte termijn passiva ( €1.6B ).
Langlopende schulden: De kortetermijnactiva van NSIS B ( €1.8B ) dekken de langetermijnschulden ( €2.6B ) niet.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 15.7% ) NSIS B wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van NSIS B is de afgelopen 5 jaar gedaald van 36.2% naar 18.1%.
Schuldendekking: De schuld van NSIS B wordt goed gedekt door de operationele kasstroom ( 44.8% ).
Rentedekking: De rentebetalingen op de schuld van NSIS B worden goed gedekt door EBIT ( 15.7 x dekking).